A New Jersey federal judge has dismissed a proposed class action suit against pharmaceutical company Amarin Corporation and its executives. The lawsuit accused the company of misleading shareholders regarding their product information and the outlook of associated patent litigation. The court ruled that the investors did not present any actionable misstatements or omissions by Amarin’s leadership. More information on the case can be found here.